Unlocking the Powerful Immune Properties of the Skin to Offer Innovative Treatments to Patients January 2020 Safe Harbor This presentation contains forward looking statements including, but not limited to, statements con

Offer Innovative Treatments to Patients January 2020Exhibit 99.1 Unlocking the Powerful Immune Properties of the Skin to Offer Innovative Treatments to Patients January 2020

Safe Harbor This presentation contains forward looking statements

including, but not limited to, statements concerning the outcome or success of DBV's clinical trials; its ability to successfully gain regulatory approvals and commercialize products; its ability to successfully advance its pipeline of product

candidates; the rate and degree of market acceptance of its products; and its ability to develop sales and marketing capabilities. Forward looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, DBV operates in

a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for DBV's management to predict all risks, nor can DBV assess the impact of all factors on its business or the extent to which any

factor, or combination of factors, may cause actual results to differ materially fromthose containedinany forwardlookingstatementsit may make. In light of these risks, uncertainties and assumptions, the forward looking events and circumstances

discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. You should not rely upon forward looking statements as predictions of future

events. Although DBV believes that the expectations reflected in the forward looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward looking

statements will be achieved or occur. Moreover, except as required by law, neither DBV nor any other person assumes responsibility for the accuracy and completeness of the forward looking statements. Forward looking statements in this presentation

represent DBV's views only as of the date of this presentation. DBV undertakes no obligation to update or review any forward looking statement, whether as a result of new information, future developments or otherwise, except as required by

law. Epicutaneous immunotherapy and Viaskin Peanut are under clinical investigation and have not been approved for marketing by any health or regulatory authority. 2Safe Harbor This presentation contains forward looking statements including,

but not limited to, statements concerning the outcome or success of DBV's clinical trials; its ability to successfully gain regulatory approvals and commercialize products; its ability to successfully advance its pipeline of product

candidates; the rate and degree of market acceptance of its products; and its ability to develop sales and marketing capabilities. Forward looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, DBV operates in

a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for DBV's management to predict all risks, nor can DBV assess the impact of all factors on its business or the extent to which any

factor, or combination of factors, may cause actual results to differ materially fromthose containedinany forwardlookingstatementsit may make. In light of these risks, uncertainties and assumptions, the forward looking events and circumstances

discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. You should not rely upon forward looking statements as predictions of future

events. Although DBV believes that the expectations reflected in the forward looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward looking

statements will be achieved or occur. Moreover, except as required by law, neither DBV nor any other person assumes responsibility for the accuracy and completeness of the forward looking statements. Forward looking statements in this presentation

represent DBV's views only as of the date of this presentation. DBV undertakes no obligation to update or review any forward looking statement, whether as a result of new information, future developments or otherwise, except as required by

law. Epicutaneous immunotherapy and Viaskin Peanut are under clinical investigation and have not been approved for marketing by any health or regulatory authority. 2

Pioneering a New Class of Immunotherapy We are focused on discovering,

developing and commercializing our novel skin immunotherapy product candidates using our proprietary Viaskin Technology Platform TM Epicutaneous immunotherapy (EPIT ) targets the immune system via intact skin with the Viaskin patch

Antigen does not enter the bloodstream, as observed in animal models EPIT has the potential to modify the immune response in a durable way to provide clinically meaningful desensitization over time for treating food allergies

Proprietary manufacturing equipment and process designed, engineered and developed by DBV 3 Epicutaneous immunotherapy and Viaskin Peanut are under clinical investigation and have not been approved for marketing by any health or regulatory

authority.Pioneering a New Class of Immunotherapy We are focused on discovering, developing and commercializing our novel skin immunotherapy product candidates using our proprietary Viaskin Technology Platform TM Epicutaneous

immunotherapy (EPIT ) targets the immune system via intact skin with the Viaskin patch Antigen does not enter the bloodstream, as observed in animal models EPIT has the potential to modify the immune response in a durable way to

provide clinically meaningful desensitization over time for treating food allergies Proprietary manufacturing equipment and process designed, engineered and developed by DBV 3 Epicutaneous immunotherapy and Viaskin Peanut are under

clinical investigation and have not been approved for marketing by any health or regulatory authority.

Merging Science and Technology to Develop Novel Viaskin Technology

Platform Patented electrostatic EPIT Activates the Immune System patch with Through Intact Skin condensation chamber allows the antigen to penetrate upper layer Electrospray: patented of epidermis patch manufacturing technology that allows for

precise antigen deposits without adjuvants Epicutaneous immunotherapy and Viaskin Peanut are under clinical investigation and have not been approved for marketing by any health or regulatory authority. 4 Dioszeghy V, et al. J Immunol.

2011;186:5629-5637. Mondoulet L, et al. Immunotherapy. 2015;7:1293-1305.Merging Science and Technology to Develop Novel Viaskin Technology Platform Patented electrostatic EPIT Activates the Immune System patch with Through Intact Skin condensation

chamber allows the antigen to penetrate upper layer Electrospray: patented of epidermis patch manufacturing technology that allows for precise antigen deposits without adjuvants Epicutaneous immunotherapy and Viaskin Peanut are under clinical

investigation and have not been approved for marketing by any health or regulatory authority. 4 Dioszeghy V, et al. J Immunol. 2011;186:5629-5637. Mondoulet L, et al. Immunotherapy. 2015;7:1293-1305.

Significant Achievements in 2019 Provide Path to Potential U.S. Approval

of Viaskin Peanut in 2H 2020 2019 1H 2020 2H 2020 Viaskin Peanut BLA accepted for review by US FDA on PEOPLE 3-year results showed Viaskin Peanut Target Action Oct. 4, 2019 durable, long-term clinical benefit Date of August 5,

2020 with an additional two years of Expansion of leadership team to meet needs of treatment Potential US launch of Viaskin evolving organization Peanut, if approved EPITOPE Part A results and Ramzi Benamar joined as

CFO on Jan. 6, 2020, bringing expectations for enrollment Potential EMA filing for deep biotechnology financial operations experience Dr. Pharis Mohideen joined as CMO, bringing extensive completion of Part B Viaskin Peanut clinical

drug development experience Adam Slatter joined as Head of Quality, PAI readiness Anticipated Viaskin Peanut FDA preparation underway Advisory Committee Increased cash position to support Viaskin Peanut pre-commercialization

Cash position of 195.8M as of 3Q 2019* Organizational structure in place to support evolution into a potential commercial-stage company U.S. launch preparation ongoing with experienced commercial team in place in

Summit, NJ 5 Epicutaneous immunotherapy and Viaskin Peanut are under clinical investigation and have not been approved for marketing by any health or regulatory authority. *3Q 2019 cash position of 73.0 million + approximately

122.8 million in net proceeds from October 2019 financingSignificant Achievements in 2019 Provide Path to Potential U.S. Approval of Viaskin Peanut in 2H 2020 2019 1H 2020 2H 2020 Viaskin Peanut BLA accepted for review by US FDA on

PEOPLE 3-year results showed Viaskin Peanut Target Action Oct. 4, 2019 durable, long-term clinical benefit Date of August 5, 2020 with an additional two years of Expansion of leadership team to meet needs of treatment

Potential US launch of Viaskin evolving organization Peanut, if approved EPITOPE Part A results and Ramzi Benamar joined as CFO on Jan. 6, 2020, bringing expectations for enrollment Potential EMA filing for deep biotechnology

financial operations experience Dr. Pharis Mohideen joined as CMO, bringing extensive completion of Part B Viaskin Peanut clinical drug development experience Adam Slatter joined as Head of Quality, PAI readiness Anticipated

Viaskin Peanut FDA preparation underway Advisory Committee Increased cash position to support Viaskin Peanut pre-commercialization Cash position of 195.8M as of 3Q 2019* Organizational structure in place to support

evolution into a potential commercial-stage company U.S. launch preparation ongoing with experienced commercial team in place in Summit, NJ 5 Epicutaneous immunotherapy and Viaskin Peanut are under clinical investigation and have not

been approved for marketing by any health or regulatory authority. *3Q 2019 cash position of 73.0 million + approximately 122.8 million in net proceeds from October 2019 financing

Peanut Allergy Places Major Burden on Patients, Families and Society 1

859,000 children ages 4-11 are diagnosed with peanut allergy in the United States 2 Significant Prevalence Most peanut allergy patients are diagnosed by 5 years of age and 80% will not outgrow their allergy Especially in Children

All peanut-allergic children are at risk of having a severe life-threatening reaction, even if they've had only 3 mild reactions in the past 4 23% of patients with peanut allergy visit the ER annually for food allergy events

and every three minutes a 5 Direct & Indirect Costs Are child goes to the emergency room for an allergic reaction to food 6 Major Burden to Health Care $4.3B in direct medical costs each year for food allergy in the United States 7

The estimated indirect economic cost of any food allergy in US children at more than $20 billion annually Fear of life-threatening reactions triggered by everyday activities leads to increased anxiety and decreased 8, 9, 10 quality

of life for patients and their families Peanut Allergy Quality of Life More than 50% of parents have missed important school functions, altered vacation plans and left a 11 is Impacted restaurant because of their child's food allergy

When asked how often parents think about their child's food allergy, 82% say it's always in the back of their 11 minds Epicutaneous immunotherapy and Viaskin Peanut are under clinical investigation and have not been

approved for marketing by any health or regulatory authority. 1. Data on file. DBV analytics. 2. FARE Peanut Allergy; Neuman-Sunshine 2012; Skolnick 2001. 3. Boyce (NIAID Guidelines) 2010, 4. 2019 Gupta et al Caregiver Survey (0-18YO) 5. Clark S,

Espinola J, Rudders SA, Banerji, A, Camargo CA. Frequency of US emergency department visits for food-related acute allergic reactions. J Allergy Clin Immunol. 2011; 127(3):682-683 6. Gupta JAMA Pediatrics 2013. 7. Cannon, H. Eric, PharmD, FAMCP. The

Economic Impact of Peanut Allergies. AJMC, 2012. 8. Greenhawt M, et al. Ann Allergy 6 Asthma Immunol. 2018; 121: 575-579. 9. Stallings VA, Oria MP. National Academies Press (US). 2017. 10. Birdi G, et al. J Allergy (Cairo). 2016; 2016:1497375. 11.

Asthma and Allergy Foundation of America. (2019). My Life With Food Allergy: Parent Survey Report. Retrieved from aafa.org/foodallergylifePeanut Allergy Places Major Burden on Patients, Families and Society 1 859,000 children ages 4-11 are

diagnosed with peanut allergy in the United States 2 Significant Prevalence Most peanut allergy patients are diagnosed by 5 years of age and 80% will not outgrow their allergy Especially in Children All peanut-allergic children are

at risk of having a severe life-threatening reaction, even if they've had only 3 mild reactions in the past 4 23% of patients with peanut allergy visit the ER annually for food allergy events and every three minutes a 5 Direct &

Indirect Costs Are child goes to the emergency room for an allergic reaction to food 6 Major Burden to Health Care $4.3B in direct medical costs each year for food allergy in the United States 7 The estimated indirect economic cost

of any food allergy in US children at more than $20 billion annually Fear of life-threatening reactions triggered by everyday activities leads to increased anxiety and decreased 8, 9, 10 quality of life for patients and their families Peanut

Allergy Quality of Life More than 50% of parents have missed important school functions, altered vacation plans and left a 11 is Impacted restaurant because of their child's food allergy When asked how often parents think about

their child's food allergy, 82% say it's always in the back of their 11 minds Epicutaneous immunotherapy and Viaskin Peanut are under clinical investigation and have not been approved for marketing by any health or regulatory

authority. 1. Data on file. DBV analytics. 2. FARE Peanut Allergy; Neuman-Sunshine 2012; Skolnick 2001. 3. Boyce (NIAID Guidelines) 2010, 4. 2019 Gupta et al Caregiver Survey (0-18YO) 5. Clark S, Espinola J, Rudders SA, Banerji, A, Camargo CA.

Frequency of US emergency department visits for food-related acute allergic reactions. J Allergy Clin Immunol. 2011; 127(3):682-683 6. Gupta JAMA Pediatrics 2013. 7. Cannon, H. Eric, PharmD, FAMCP. The Economic Impact of Peanut Allergies. AJMC,

2012. 8. Greenhawt M, et al. Ann Allergy 6 Asthma Immunol. 2018; 121: 575-579. 9. Stallings VA, Oria MP. National Academies Press (US). 2017. 10. Birdi G, et al. J Allergy (Cairo). 2016; 2016:1497375. 11. Asthma and Allergy Foundation of America.

(2019). My Life With Food Allergy: Parent Survey Report. Retrieved from aafa.org/foodallergylife

Avoidance Isn't Enough for Patients: Goal Is to Offer Additional

Protection to Address This Unmet Need 1,2 Top Priority Treatment Goals for Caregivers and Physicians are the Same--They Are Seeking a Treatment That: 1. Reduces the likelihood of an allergic reaction in case of accidental exposure 2. Low risk of a

serious reaction caused by the treatment and low side effects 3. Treatment is accepted by the caregiver and child Quantitative modeling suggests desensitization therapies could offer significant reduction of the risks associated with 3, 4, 5

accidental exposures by increasing the dose of peanut protein at which patients react (the eliciting dose) 1 mg 3 mg 10 mg 30 mg 100 mg 300 mg 1000 mg 1 peanut is ~250-300 mg >95% Risk Reduction* Epicutaneous immunotherapy and Viaskin

Peanut are under clinical investigation and have not been approved for marketing by any health or regulatory authority. 1. Greenhawt M, et al. Ann Allergy Asthma Immunol. https://doi.org/10.1016/j.anai.2018.06.018 2. Based on primary market research

among 100 allergists in the United States. Survey question: If a new peanut allergy desensitization treatment for children 4 to 11 years of age became FDA approved and available for use, what would be the importance of each of the following

attributes to you? Please use a 0- to 7-point scale where 0 means "not at all important to me" and 7 means "very important to me." 3. Remington, B, et al. Ann Allergy Asthma Immunol. doi:

http://dx.doi.org/10.1016/j.anai.2017.08.224, Baumert JL, et al. J Allergy Clin Immunol Pract. 2017. doi:10.1016/j.jaip.2017.05.006. 4. Shreffler W, et al. Ann Allergy Asthma Immunol 2017; 1081-1206. 5. Remington, B et al. ACAAI 2018 #A302. 7 *The

QRA model inputs variables including the clinical threshold for peanut-allergic individuals and the exposure dose of peanut residue to predict the allergenic risk associated with the exposure to residual peanut protein. This model is based on a

previous model and was modified to incorporate a Bayesian framework to better estimate the risk of allergic reaction.Avoidance Isn't Enough for Patients: Goal Is to Offer Additional Protection to Address This Unmet Need 1,2 Top Priority

Treatment Goals for Caregivers and Physicians are the Same--They Are Seeking a Treatment That: 1. Reduces the likelihood of an allergic reaction in case of accidental exposure 2. Low risk of a serious reaction caused by the treatment and low side

effects 3. Treatment is accepted by the caregiver and child Quantitative modeling suggests desensitization therapies could offer significant reduction of the risks associated with 3, 4, 5 accidental exposures by increasing the dose of peanut protein

at which patients react (the eliciting dose) 1 mg 3 mg 10 mg 30 mg 100 mg 300 mg 1000 mg 1 peanut is ~250-300 mg >95% Risk Reduction* Epicutaneous immunotherapy and Viaskin Peanut are under clinical investigation and have not been approved

for marketing by any health or regulatory authority. 1. Greenhawt M, et al. Ann Allergy Asthma Immunol. https://doi.org/10.1016/j.anai.2018.06.018 2. Based on primary market research among 100 allergists in the United States. Survey question: If a

new peanut allergy desensitization treatment for children 4 to 11 years of age became FDA approved and available for use, what would be the importance of each of the following attributes to you? Please use a 0- to 7-point scale where 0 means

"not at all important to me" and 7 means "very important to me." 3. Remington, B, et al. Ann Allergy Asthma Immunol. doi: http://dx.doi.org/10.1016/j.anai.2017.08.224, Baumert JL, et al. J Allergy Clin Immunol Pract. 2017.

doi:10.1016/j.jaip.2017.05.006. 4. Shreffler W, et al. Ann Allergy Asthma Immunol 2017; 1081-1206. 5. Remington, B et al. ACAAI 2018 #A302. 7 *The QRA model inputs variables including the clinical threshold for peanut-allergic individuals and the

exposure dose of peanut residue to predict the allergenic risk associated with the exposure to residual peanut protein. This model is based on a previous model and was modified to incorporate a Bayesian framework to better estimate the risk of

Epicutaneous Immunotherapy Is an Innovative Approach to Potentially

Offer Long-Term Benefit Protection from Long-Term Sustained Accidental Exposure Maintenance of Effect Unresponsiveness EPIT Utilizes the Immune Tolerizing Large Dataset of 141 Children Treated OLFUS and PEOPLE Show Potential for Properties of the

Skin for Three Years in PEOPLE Sustained Protection Differentiated proposed mechanism, Patients demonstrated durable, long- Month-38 DBPCFC to explore including potentially promoting term clinical benefit with an "sustained

unresponsiveness" sustained effect additional two years of treatment In PEOPLE, 77.8% (14/18) of the Takes time for immune system to Low discontinuations due to adverse children who completed the oral induce protective

response events observed food challenge at Month 38, after EPIT-induced Tregs observed to have Largest long-term peanut allergy two months off treatment with pronounced immunosuppressive immunotherapy trial to date, with peanut-free

diet,* maintained functionality high compliance enabling extended desensitization with an ED 1,000 mg study participation Ultimate goal of any food allergen immunotherapy is long-term tolerance 8 Epicutaneous immunotherapy and Viaskin

Peanut are under clinical investigation and have not been approved for marketing by any health or regulatory authority. *All participants who reached an ED 1,000 mg at Month 36 were eligible to continue the study for two additional months

without treatment and required to maintain a peanut-free diet. An oral food challenge was administered at the end of this period (Month 38). Epicutaneous Immunotherapy Is an Innovative Approach to Potentially Offer Long-Term Benefit Protection from

Long-Term Sustained Accidental Exposure Maintenance of Effect Unresponsiveness EPIT Utilizes the Immune Tolerizing Large Dataset of 141 Children Treated OLFUS and PEOPLE Show Potential for Properties of the Skin for Three Years in PEOPLE Sustained

Protection Differentiated proposed mechanism, Patients demonstrated durable, long- Month-38 DBPCFC to explore including potentially promoting term clinical benefit with an "sustained unresponsiveness" sustained effect

additional two years of treatment In PEOPLE, 77.8% (14/18) of the Takes time for immune system to Low discontinuations due to adverse children who completed the oral induce protective response events observed food challenge at

Month 38, after EPIT-induced Tregs observed to have Largest long-term peanut allergy two months off treatment with pronounced immunosuppressive immunotherapy trial to date, with peanut-free diet,* maintained functionality high

compliance enabling extended desensitization with an ED 1,000 mg study participation Ultimate goal of any food allergen immunotherapy is long-term tolerance 8 Epicutaneous immunotherapy and Viaskin Peanut are under clinical